AstraZeneca has patented a method for treating atherosclerotic cardiovascular disease by administering statin pharmaceutical compositions to qualified subjects. The method involves a computer system analyzing various factors to determine eligibility for the medication. This innovative approach aims to effectively manage cholesterol levels in patients. GlobalData’s report on AstraZeneca gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AstraZeneca, Personalized cancer vaccines was a key innovation area identified from patents. AstraZeneca's grant share as of May 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Method for managing cholesterol in a subject
A recently granted patent (Publication Number: US12002558B2) outlines a method for managing cholesterol in a subject using a computer system. The method involves receiving a request for a statin pharmaceutical composition, obtaining detailed information about the subject including age, gender, medical history, and risk factors, and comparing this information against various filters to determine eligibility for the medication. Filters include criteria such as age, pregnancy status, drug interactions, cardiovascular events, and more. If the subject passes all filters, they must acknowledge any warnings before receiving the statin pharmaceutical composition. The method also includes administering the medication to the subject upon authorization.
Furthermore, the patent includes additional details such as considering medication interactions, cardiovascular events like heart procedures, and using a pooled cohort equation to calculate the subject's risk of developing atherosclerotic disease. The method also involves providing warnings based on filters fired during the comparison process, such as age, pregnancy, drug interactions, and more. The patent emphasizes the importance of thorough evaluation and communication with the subject before authorizing the provision of the statin pharmaceutical composition, ensuring a personalized approach to managing cholesterol levels in individuals.
To know more about GlobalData’s detailed insights on AstraZeneca, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
